Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 02, 2026 07:00 ET | Source: Skye Bioscience, Inc.

Skye Bioscience Treats First Patient in Nimacimab Higher-Dose Expansion Study Evaluating Exposure-Response to Inform Phase 2b Dose Selection for GLP-1 Combination Development

SAN DIEGO, April 02, 2026 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”) a clinical-stage biotechnology company focused on unlocking new therapeutic pathways for obesity and other...
April 02, 2026 07:00 ET | Source: Adagene Inc.

Updated Data from Phase 1b/2 Study of Muzastotug in Combination with KEYTRUDA® (pembrolizumab) in Late-line Patients with Microsatellite Stable Colorectal Cancer Demonstrate Improved Durability of Response

Dose-Dependent Efficacy Results: As of the latest data cut, muzastotug achieved a 31% (8/26) confirmed overall response rate (ORR) in the combined 20 mg/kg dose cohorts, showing a clear improvement...
April 01, 2026 18:22 ET | Source: CREDICORP LTD. C/O BANCO DE CREDITO

Credicorp Ltd.: Credicorp Announces Three New Directors, Reelection of Six Existing Directors, and New Committee Composition

Lima, April 01, 2026 (GLOBE NEWSWIRE) -- Lima, Peru – April 1, 2026 – Credicorp Ltd. (“Credicorp” or “the Company”) (NYSE: BAP), the leading financial services holding company in Peru with presence...
April 01, 2026 17:12 ET | Source: Beam Therapeutics

Beam Therapeutics Announces Publication of BEACON Phase 1/2 Data for risto-cel in Patients with Sickle Cell Disease (SCD) in The New England Journal of Medicine

Prestigious Publication Reinforces risto-cel’s Durable, Differentiated Clinical Data for the Treatment of SCD with Severe Vaso-occlusive Crises (VOCs) Initially Presented at ASH, Data from 31...
April 01, 2026 17:00 ET | Source: Adagene Inc.

Adagene Reports Full Year 2025 Financial Results and Provides Corporate Update

In 2025, muzastotug showed 29% confirmed overall response rate (ORR) among 21 patients with MSS CRC in the 20 mg/kg dose cohorts Median overall survival (OS) for the 10 mg/kg cohorts was 19.4...
April 01, 2026 16:15 ET | Source: ARMOUR Residential REIT, Inc.

ARMOUR Residential REIT, Inc. Confirms April 2026 Common Share and Q2 2026 Series C Preferred Share Dividends

VERO BEACH, Florida, April 01, 2026 (GLOBE NEWSWIRE) -- ARMOUR Residential REIT, Inc. (NYSE: ARR and ARR-PRC) (“ARMOUR” or the “Company”) today confirmed the April 2026 cash dividend for the...
April 01, 2026 10:00 ET | Source: Origin Modern Health & Wellness

Origin Health Unveils Newly Redesigned Website and Announces Open Registration for 2nd Annual Guardian Initiative Charity Golf Tournament

SAN DIEGO, April 01, 2026 (GLOBE NEWSWIRE) -- Origin Modern Health & Wellness, a leader in integrative and regenerative healthcare, today announced the official launch of its newly redesigned...
April 01, 2026 09:50 ET | Source: Faruqi & Faruqi LLP

ATRA UPCOMING DEADLINE: Faruqi & Faruqi, LLP Reminds Atara Biotherapeutics (ATRA) Investors of Securities Class Action Deadline on May 22, 2026

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Atara To Contact Him Directly To Discuss Their Options If you purchased or...
April 01, 2026 08:00 ET | Source: Apollo Global Management, Inc.

Apollo Funds Acquire Gatehouse Living Group from Gatehouse Bank

NEW YORK, April 01, 2026 (GLOBE NEWSWIRE) -- Apollo (NYSE: APO) today announced that Apollo-managed funds have acquired Gatehouse Living Group (“GLG” or “the Group”), a vertically integrated UK...
April 01, 2026 08:00 ET | Source: Cogent Biosciences, Inc.

Cogent Biosciences Announces Submission of New Drug Application for Bezuclastinib in Gastrointestinal Stromal Tumors (GIST)

Bezuclastinib NDA submitted under the FDA’s RTOR program based on positive results from Phase 3 PEAK trial; bezuclastinib previously granted Breakthrough Therapy Designation in GISTBezuclastinib...